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ABSTRACT  
Background: Bibliometric analysis highlights the key topics and publications which have 
shaped the understanding and management of Gastric cancer. Here the 100 most cited 
manuscripts in the field of gastric cancer (GC) are analyzed.  
Methods: The Thomson Reuters Web of Science database with the search terms 'gastric 
cancer’ or ‘gastric carcinoma’ or ‘stomach cancer’ or ‘stomach carcinoma’ or 
‘gastroscopy was used to identify all English language full manuscripts for the study. The 
100 most cited papers were further analysed by topic, journal, author, year and 
institution.  
Results: 122,616 eligible papers were returned and the median (range) citation number 
was 417 (2893 to 299). The most cited paper (by Parsonnet) focused on H.Pylori risk and 
gastric cancer (2893 citations). Cancer Research published the highest number of papers 
(n=13, 6901 citations), The New England Journal of Medicine (NEJM) had the most 
citations (n=8, 9358 citations). The country and year with the greatest number of 
publications were the USA (n=29), and 1998 (n=10). The most ubiquitous topic was the 
pathology of gastric cancer (n=57) followed by Aetiology of gastric cancer (n=47), and 
basic science of gastric cancer (n=44). 
Conclusion: The most cited manuscripts highlighted in this study describe the science 
related to the pathogenesis of GC including surgery and regimens that have resulted in 
the contemporary understanding and treatment of GC. This work provides the most 
influential references related to GC and serves as a guide as to what makes a citable 
paper.  
  
MINI-ABSTRACT 
 
Bibliographic analysis of the top 100 cited gastric cancer (GC) publications describing 
the science related to the pathogenesis of GC, and documenting management advances. 
INTRODUCTION   
Gastric cancer (GC) is a significant cause of morbidity and mortality worldwide 
and there is a growing body of evidence encompassing the pathological, clinical, 
oncological radiological and basic science features of the disease. Improvements in the 
global knowledge base continue apace and underpin better treatments and improved 
survival.  
The establishment of a citation rank list identifies published work that has had the 
greatest intellectual influence [1]. A citation is received when a publication is referenced 
by another peer-reviewed article. Work that has the greatest impact on the scientific 
community is likely to be cited many times. Citation analysis involves ranking and 
evaluating an article or journal based on the number of citations it receives. In addition to 
determining the most frequently cited articles, this analysis is also used to rank journals 
in terms of impact [1].  
Many medical specialties have utilised the citation rank analysis to identify the 
most influential papers in their field which includes; trauma and orthopaedic surgery [2], 
plastic surgery [3], general surgery [4] and oncology [5].  To date, no study has been 
undertaken to determine the most influential papers in the field of gastric cancer. 
Analysis of these data provides insight into how our understanding of gastric cancer has 
developed and how this information has changed our management of the disease. 
Additionally, this work serves as a reference for the most cited papers in gastric cancer. 
The aim of this study was to determine the topics and specifically the studies that have 
been most influential during this time of improved understanding and management of 
gastric cancer. 
METHODS  
A search of the Thomson Reuters Web of Science citation indexing database and research 
platform was completed using the search terms ‘gastric cancer’ or ‘gastric carcinoma’ or 
‘stomach cancer’ or ‘stomach carcinoma’ or ‘gastroscopy’. The returned dataset was 
filtered to include only English language and full manuscripts and sorted by number of 
citations; a method initially developed by Paladugu and colleagues (4). The 100 most 
cited manuscripts were identified from the large number of manuscripts returned. The 
dataset was then further evaluated examining title, first and senior author, institution and 
department of the first author, topic, year of publication and the country of origin. The 
individual and 5 year impact factors (both for the year 2013) of each journal publishing 
the manuscripts was recorded.  
  
RESULTS  
The Web of Science search returned 122,616 full-length, English language papers. Table 
1 lists the 100 most cited of these papers [6-105]. The number of citations ranged from 
2893 for Parsonnet et al (Helicobacter-Pylori infection and the risk of gastric carcinoma) 
[6] to 299 for Fukushige et al (Localization of a Novel v-erbB-Related Gene, c-erbB-2, 
on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line) [105]. 
The oldest manuscript featured in the top 100 was by Aird et al (A relationship between 
cancer of stomach and the ABO blood groups) and published in 1953 [45]. The most 
recent manuscripts were published by the Japanese Gastric Cancer Association in 2011 
and looked at the classification and treatment of gastric cancer [68, 70]. 
The 100 most influential papers were across 36 journals with the number of 
manuscripts per journal ranging from 1 to 13 (Table 2). Although Cancer Research 
published the most papers (n=13 and 6901 citations), The New England Journal of 
Medicine (NEJM) had the most citations (n=8 and 9358 citations). The NEJM also had 
the highest impact factor (54.420) and 5 year impact factor (50.810).  
The country with the greatest number of publications in the top 100 was the 
United States of America (USA) with 29 publications followed by Japan with 28 
publications (figure 1). The National Cancer Institute Bethesda had the highest amount of 
citations with 3605 and was the joint highest institution for number of publications in the 
top 100 with 4 manuscripts (table 3).  Ten authors had 2 first author publications in the 
top 100. Professor Julie Parsonnet, George DeForest Barnett Professor in Medicine, 
Stanford University had the highest volume of citations with 3504. This was followed by 
Naomi Uemura, Director of the National Center for Global Health and Medicines 
Kohnodai Hospital in Ichikawa had 2380 citations and Professor Pelayo Correa, Anne 
Potter Wilson Chair in Medicine and Professor of pathology, Microbiology and 
Immunology, Vanderbilt University Medical Center had 2049 citations. Manuel 
Sobrinho-Simões, Professor of Cancer biology at the Institute of molecular Pathology and 
Immunology of the University of Porto (Ipatimup) had 3 senior author publications in the 
top 100 with 1066 citations. Despite this, the senior author with the most citations was 
Professor Richard K Sibley (2893), Professor of Pathology, Stanford School of Medicine 
for his paper ‘Helicobacter-Pylori infection and the risk of gastric carcinoma’ [6].  
 A possible limitation of this type of study is that historical manuscripts may 
accrue a larger number of citations despite lacking the impact of newer publications. To 
control for this, the number of citations were divided by the number of years since 
publication to give a citation rate (table 4) [6, 7, 10, 11, 12, 16, 21, 30, 68, 70]. The 
citation rate for the top 10 manuscripts ranged from 255 for Bang et al (Trastuzumab in 
combination with chemotherapy versus chemotherapy alone for treatment of HER2-
positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, 
open-label, randomised controlled trial) [12] to 81 for Crew et al (Epidemiology of 
gastric cancer) [21]. Japan had the most papers in the top 10 citation rate with 5 followed 
by USA with 4 and South Korea with 1.  
 Pathology of gastric cancer was the topic most widely studied with 57 of the top 
100 papers covering the topic (table 5). Forty seven manuscripts looked at the aetiology 
of gastric cancer of which 44 were scientific papers.  Thirty papers studied the prognostic 
basis of clinicopathological factor with 20 papers describing clinical trials of which 19 
were covering management. Four papers were consensus statements of guidelines.   
 
  
DISCUSSION  
Gastric cancer is the third leading cause of cancer death accounting for approximately 
723,000 deaths worldwide in 2012 [106]. Disease incidence and outcomes of treatment 
vary globally with the Republic of Korea, Mongolia and Japan reporting incidence rates 
per 100,000 population as high as 41.8, 32.5 and 29.9 compared to Botswana and 
Mozambique with rates of 0.9 and 0.9 respectively [106]. Despite this the principles of 
treatment are consistent. The understanding of the aetiological factors at play and how 
genetic aberrations relate to pathogenesis has led to improvements in patient 
prognostication and management. The results of the current study confirm that these 
topics were highly represented with 76 manuscripts of the top 100 influential papers 
covering these areas. More recently published manuscripts had a higher citation rate, 
which suggests a significant influence within the top 100 within the next 5 to 10 years.   
Influential publications are more likely to be cited by the scientific community 
and these citations form the basis of the impact factor. The impact factor of a journal 
quantifies the average citations of the manuscripts published within the journal during a 
specific period. Therefore, journals with a higher impact factor are recognized as being of 
a higher quality and more likely to contain influential publications. Journals with very 
high impact factors (54.420 – 30.387); NEJM, Nature, Cell and Science, JAMA and 
Lancet only represent 19% of all publications in the top 100. Furthermore, the median 
impact factor was 9.284 and 25% of publications were in journals with an impact factor 
of 4.900 or less. A possible explanation for this relates to the novelty of the results. 
Novelty can be classified as relating to science in general or only gastric cancer. Findings 
that have already been established in other cancers may then be re-established in gastric 
cancer. These manuscripts are unlikely to be published in high impact factor journals, 
however, within the context of this study they are likely to be considered influential.    
 On review of the topics covered in the top 100, pathology and more specifically 
the aetiology and pathophysiology of gastric cancer was well studied with 47 
manuscripts. Helicobacter Pylori infection and its association with gastric cancer 
development accounts for 14 papers in the top 100 and is also the most highly cited 
manuscript [6]. Other topics included aetiology (47%), basic science (44%), genetics 
(31%), prognosis (30%), epidemiology (22%), clinical trials (20%), management (19%), 
surgery (15%) and chemotherapy (10%). Despite surgery remaining the mainstay of 
treatment and the only potential cure for gastric cancer; however, it was only represented 
in 15 manuscripts of the top 100 and is therefore relatively under represented. Of these 15 
surgical related manuscripts, nearly half examined the role of the extended D2 
lymphadenectomy in gastric cancer survival and report the results of clinical trials. The 
importance of these topics is confirmed by their publication in high impact factor 
journals; NEJM, Lancet and Journal of Clinical Oncology.  
Even with advances in surgical techniques and perioperative care, five year 
survival rates for patients with potentially curable gastric cancer in the UK remain at 
approximately 50%. Consequently, there has been a greater effort in developing 
chemotherapeutic agents and the emergence of these studies in the top 100 confirms their 
importance to the scientific community. The majority of studies have looked at 
chemotherapy regimens in advanced gastric cancer with only two publications, a 
metanalysis of randomized trials by Earle et al. [94] and a randomized control trial by 
Sakuramoto et al. [16], looking at adjuvant chemotherapy in patients undergoing 
potentially curative resection. The recent heightened importance of chemotherapy based 
studies is reflected by their publication in higher impact factor journals such as NEJM, 
Lancet and Journal of Clinical Oncology.   
The main limitation of this manuscript is the potential for several types of bias, 
which may affect results. Disproportionate citation may result from institutional bias, 
language biases, self citation or powerful person bias. In addition, older journals may 
receive more citations. Although an attempt to control for this has been made by using 
the citation rate index, it may take a number of years for influential manuscripts to accrue 
citations due to the publication lead-time for their citing manuscript. Therefore, recently 
published manuscripts that have reached enough citations for inclusion in the top 100 
have added importance. A further limitation is the inclusion of only first and senior 
authors and the institution of the first author. It is possible that several first authors will 
have co-authored other papers in the top 100 and are therefore under represented in the 
current study format. 
CONCLUSION  The most cited manuscripts highlighted in the current study describe 
the basic science related to the aetiology and pathogenesis of gastric cancer in addition to 
the surgical techniques and associated treatment regimens that have resulted in the 
contemporary understanding and improved treatment outcomes of gastric cancer. 
Arguably, given the perceived relative lack of novelty to the science community in 
general, the majority of manuscripts were published in journals with impact factors of 
less than 10. In addition to providing a reference of what could be considered as the most 
influential papers in gastric cancer, this work serves as a reference for researchers and 
clinicians alike as to what makes a citable paper in the arena of gastric cancer study. This 
study also suggests that newer manuscripts have a higher citation rate, which will have a 
significant impact on the top 100 within the next 5-10 years.   
 
  
TABLE AND FIGURE LEGENDS  
Table 1. The Top 100 Cited Paper in Gastric Cancer. Manuscripts without a first author 
are specified with *   
Table 2. Journals with the Top 100 Cited Gastric Cancer Papers   
Table 3. Institutions with the Highest Number of Papers in the Top 100  
Table 4. Authors with the Highest Number of Papers in the Top 100  
Table 5. The Top 10 Cited Papers in CRC  
Table 6. Most Frequently Referenced Topics *Numbers may not add up to 100 and 
numbers within each group may not add up to total in each group due to an overlap of 
subjects covered in the individual manuscripts   
Figure 1. Proportion of citations from each country  
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Table 1. The Top 100 Cited Paper in Gastric Cancer.  
Rank Citations First Author  Rank Citations First Author 
1 2893 Parsonnet, J6  51 416 Kelley, J56 
2 2002 Uemura, N7  52 405 Toyota, M57 
3 1697 Correa, P8  53 404 Siewert, J58 
4 1485 Nomura, A9  54 399 Mayer, B59 
5 1464 El-Omar, E10  55 393 Hansson, L60 
6 1417 Devesa, S11  56 389 Rosivatz, E61 
7 1276 Bang, Y12  57 389 Yasumoto, K62 
8 1093 Forman, D13  58 389 Hohenberger, P63 
9 937 Bonenkamp, J14  59 386 Figueiredo, C64 
10 894 Guilford, P15  60 386 Morson B65 
11 811 Sakuramoto, S16  61 383 Yoo, C66 
12 782 Ono, H17  62 378 Uemura, N67 
13 
774 Houghton, J18 
 63 
376 
*Japanese Gastric 
Cancer Association68 
14 750 Li, Q19  64 372 Fukase, K69 
15 
749 Cuschieri, A20 
 65 
370 
*Japanese Gastric 
Cancer Association70 
16 733 Crew, K21  66 367 Hofmann, M71 
17 729 Van Cutsem, E22  67 361 Xia, L72 
18 726 Forman, D23  68 357 Nakajima, T73 
19 717 Ristimaki, A24  69 356 Hundahl, S74 
20 711 Watanabe, T25  70 353 Wang, T75 
21 711 Siewert, J26  71 352 Correa, P76 
22 687 Wong, B27  72 350 Dent, D77 
23 666 Bonekamp, J28  73 349 Sasako, M78 
24 649 Becker, K29  74 349 Songun, I79 
25 641 Koizumi, W30  75 346 Machado, J80 
26 611 Parsonnet, J31  76 344 Shimoyama, Y81 
27 579 Maeda, K32  77 341 Farrow, D82 
28 572 Cuschieri, A33  78 341 Vaughn, T83 
29 563 Huang, J34  79 336 Martin, H84 
30 554 El-Omar, E35  80 334 Machado, J85 
31 554 Howson, C36  81 334 Maruyama, K86 
32 523 Wagner, A37  82 333 Yang, L87 
33 518 Lu, C38  83 328 Sakamoto, H88 
34 517 Pyrhonen, S39  84 321 Ichihara, F89 
35 514 Mirvish, S40  85 319 Oka, S90 
36 506 Han, H41  86 316 Honda, S91 
37 502 Petrocca, F42  87 316 Gravalos, C92 
38 488 Fuchs, C43  88 311 Ernst, P93 
39 468 Hartgrink, H44  89 311 Earle, C94 
40 467 Aird, I45  90 310 Noguchi, Y95 
41 462 Murad, A46  91 308 Tanner, M96 
42 455 Glimelius, B47  92 307 Engel, L97 
43 447 Wanebo, H48  93 306 Fleisher, A98 
44 444 Sakata, Y49  94 305 Yasui, W99 
45 442 Huscher, C50  95 304 Imai, S100 
46 437 Webb, P51  96 303 Yonemura, Y101 
47 436 Myeroff, L52  97 303 Leung, S102 
48 427 Ming, S53  98 302 Roder, J103 
49 418 Haenszel, W54  99 302 Takaishi, S104 
50 417 Park, K55  100 299 Fukushige, S105 
  
Table 2. Journals with the Top 100 Cited Colorectal Cancer Papers  
Journal title 
Impact 
Factor 
as of 
2015 
5 Year 
Impact 
Factor 
Number of 
Manuscripts 
in the Top 100 
Number of 
citations 
American Journal of Pathology 4.602 5.330 1 389 
Annals of Oncology 6.580 6.470 3 1079 
Annals of Surgery 7.188 8.260 4 1934 
Annual Review of Microbiology 13.018 15.210 1 311 
British Journal of Surgery 5.210 4.960 3 1137 
British Medical Journal 14.093 13.511 2 1560 
British Journal of Cancer 4.820 5.210 3 1652 
Cancer 4.901 5.690 9 4719 
Cancer Cell 23.893 26.640 1 502 
Cancer Epidemiology, Biomarkers & 
Prevention 
4.324 4.700 3 1060 
Cancer Research 9.284 8.958 13 6901 
Cell 33.116 34.774 1 750 
Clinical Cancer Research 8.193 7.830 2 624 
Epidemiologic Reviews 7.333 19.050 1 554 
European Journal of Cancer 4.820 5.260 2 755 
Gastric Cancer 4.828 3.620 3 1103 
Gastroenterology 13.93 12.840 6 2861 
Gastrointestinal endoscopy 4.900 5.280 1 319 
GUT 13.319 9.990 3 1880 
Histopathology 3.301 3.510 1 367 
International Journal of Cancer 5.007 5.470 2 697 
JAMA 30.387 29.270 1 687 
Japanese Journal of Cancer Research 2.225 0 1 418 
Journal of Clinical Epidemiology 5.478 3.600 1 416 
Journal of Clinical Oncology 17.880 17.260 3 1720 
Journal of the National Cancer Institute 15.161 14.790 2 693 
Lancet 39.207 39.315 6 4001 
Lancet Oncology 24.725 24.229 2 990 
Molecular and Cellular Biology 5.036 6.370 1 299 
Nature 42.351 38.160 2 2358 
New England Journal of Medicine 54.420 50.810 8 9358 
Proceedings of the National Academy of 
Sciences of the United States of America 
9.809 10.580 3 1049 
Science 31.477 32.450 1 774 
Stem Cells 7.133 8.370 1 302 
The Journal of Biological Chemistry 4.600 5.020 1 389 
World Journal of Gastroenterology 2.433 2.590 2 1066 
 
 
 
 
 
 
Table 3. Institutions with the highest number of papers in the top 100  
Institution 
Number of publication 
in top 100 
Total number 
of citations 
Technische Universität München 4 1806 
National Cancer Institute Bethesda 4 3605 
University of porto 3 1066 
Osaka University 3 1396 
National Cancer Center Hospital 3 1465 
Leiden University Medical Center 3 1754 
Hiroshima University School of Medicine 3 1002 
University of Washington 2 682 
University of Uppsala 2 848 
Stanford University School of Medicine 2 3504 
Oxford University 2 1819 
Ninewells Hospital and Medical School 2 1321 
National cancer center research institute 
tskuijii 2 672 
Louisiana State University Medical Centre 2 2049 
Kyoto prefectural university of medicine 2 746 
Kitasato University School of Medicine 2 1452 
Kanazawa University 2 692 
Columbia University 2 1035 
 
 
 
 
Table 4. Top 10 papers with the highest citation rate  
Rank Citation 
rate 
First author Senior author Title Institution Country 
1 255 Bang, Y12 Kang, Y Trastuzumab in combination with chemotherapy versus 
chemotherapy alone for treatment of HER2-positive advanced gastric 
or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, 
randomised controlled trial 
Seoul National 
University College of 
Medicine 
South 
Korea 
2 143 Uemura, N7 Schlemper, R Helicobacter pylori Infection and the Development of Gastric Cancer Fukuoka University 
School of Medicine 
Japan 
3 121 Parsonnet, J6 Sibley, R Helicobacter-Pylori infection and the risk of gastric cancer  Stanford University 
School of Medicine 
USA 
4 101 Sakuramoto, 
S16 
Arai, K Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral 
Fluoropyrimidine 
Kitasato University 
School of Medicine 
Japan 
5 98 El-Omar, E10 Rabkin, C Interleukin-1 polymorphisms associated with increased risk 
of gastric cancer 
National Cancer 
Institute Bethesda 
USA 
6 94 Japanese 
Gastric Cancer 
Association68 
Japanese 
Gastric Cancer 
Association 
Japanese classification of gastric carcinoma: 3rd English edition Kyoto prefectural 
university of 
medicine 
Japan 
7 93 Japanese 
Gastric Cancer 
Association70 
Japanese 
Gastric Cancer 
Association 
Japanese gastric cancer treatment guidelines 2010 (ver. 3) Kyoto prefectural 
university of 
medicine 
Japan 
8 92 Koizumi, W30 Takeuchi, M S1 plus cisplatin versus S-1 alone for first-line treatment of advanced 
gastric cancer (SPIRITS trial): a phase III trial 
Kitasato University 
School of Medicine 
Japan 
9 83 Devesa, S11 Fraumeni, J Changing Patterns in the Incidence of Esophageal and Gastric 
Carcinoma in the United States 
National Cancer 
Institute Bethesda 
USA 
10 81 Crew, K21 Neugut, A Epidemiology of gastric cancer Columbia University USA 
 
 
 
 
  
Table 5. Most frequently referenced topics  
Subject Number of papers 
Pathology 57 
Aetiology / Pathophysiology 47 
Science 44 
Genetics 31 
Prognosis 30 
Epidemiology 22 
Clinical trials 20 
Management 19 
Surgery 15 
Chemotherapy 10 
Consensus statement / 
Guidelines 4 
 
* Due to overlap of topics, cell numbers do not add up to 100 
Figure 1. Proportion of citations by country 
 
